← Back to Search

PET Scan with DPA-714 for Parkinson's Disease

Phase 1 & 2

Recruiting

Led By Jonathan McConathy, MD

Research Sponsored by University of Alabama at Birmingham

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

Study Summary

This trial will measure the level of neuroinflammation in the brains of people with Parkinson's disease compared to healthy controls, using a PET scan with the tracer [18F]DPA-714.

Who is the study for?

This trial is for participants already enrolled in the UAB Neuroinflammation in Parkinson's Disease study. It's specifically for those who can undergo PET/MRI scans and are not pregnant or at risk of pregnancy. Individuals must have a certain genetic profile (high or mixed affinity binder) that allows them to bind well with the imaging agent used.Check my eligibility

What is being tested?

The substudy is testing how a PET tracer called [18F]DPA-714 distributes and concentrates in the brain, which could indicate levels of neuroinflammation in Parkinson’s patients compared to healthy individuals. The tracer binds to proteins associated with inflammation in brain immune cells.See study design

What are the potential side effects?

While specific side effects are not listed, typical risks may include reactions to the PET tracer, discomfort from lying still during imaging, and potential issues related to MRI such as claustrophobia or reactions to contrast agents if used.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Comparison of TSPO-PET measures of neuroinflammation between PD patients and healthy controls.

Correlation of DPA-714-PET/MRI with demographics, clinical and biospecimen assessments from Neuroinflammation in PD study

Trial Design

4Treatment groups

Experimental Treatment

Group I: UDALL 5-year Follow-up CohortExperimental Treatment1 Intervention

n-67 from baseline early Parkinson's disease cohort

Group II: Metabolite Analysis CohortExperimental Treatment1 Intervention

n-5 from baseline early Parkinson's disease cohort

Group III: Baseline Cohort Healthy Controls, DPA-714-PET/MRIExperimental Treatment1 Intervention

n-105

Group IV: Baseline Cohort Early Parkinson's Disease, DPA-714-PET/MRIExperimental Treatment1 Intervention

n-100

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor

1,590 Previous Clinical Trials

2,281,149 Total Patients Enrolled

Jonathan McConathy, MDPrincipal InvestigatorUniversity of Alabama at Birmingham

2 Previous Clinical Trials

180 Total Patients Enrolled

Media Library

DPA-714-PET/MRI Clinical Trial Eligibility Overview. Trial Name: NCT03457493 — Phase 1 & 2

Parkinson's Disease Research Study Groups: Baseline Cohort Healthy Controls, DPA-714-PET/MRI, Metabolite Analysis Cohort, Baseline Cohort Early Parkinson's Disease, DPA-714-PET/MRI, UDALL 5-year Follow-up Cohort

Parkinson's Disease Clinical Trial 2023: DPA-714-PET/MRI Highlights & Side Effects. Trial Name: NCT03457493 — Phase 1 & 2

DPA-714-PET/MRI 2023 Treatment Timeline for Medical Study. Trial Name: NCT03457493 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is participation in this research endeavor still open to volunteers?

"According to the data found on clinicaltrials.gov, this medical experiment is currently accepting participants. The trial was initially posted in March 2018 and has been most recently updated on March 29th 2022."

Answered by AI

What is the scope of individuals currently participating in this research?

"Affirmative. Clinicaltrials.gov states that the research program, which was initialised on March 22nd 2018, is currently recruiting applicants. The study necessitates 20 individuals over a single centre to complete it."

Answered by AI